Galenica Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Galenica is de winst gegroeid met een gemiddeld jaarlijks percentage van 3.1%, terwijl de Healthcare industrie de winst jaarlijks groeide met 11.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 3% per jaar. Het rendement op eigen vermogen van Galenica is 12.1%, en het heeft een nettomarge van 4.5%.
Belangrijke informatie
3.1%
Groei van de winst
2.8%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 13.4% |
| Inkomstengroei | 3.0% |
| Rendement op eigen vermogen | 12.1% |
| Nettomarge | 4.5% |
| Volgende winstupdate | 11 Mar 2025 |
Recente prestatie-updates uit het verleden
Recent updates
Galenica AG's (VTX:GALE) Popularity With Investors Is Under Threat From Overpricing
Nov 12
Galenica (VTX:GALE) Seems To Use Debt Quite Sensibly
Oct 05Galenica (VTX:GALE) Might Have The Makings Of A Multi-Bagger
Sep 17Earnings Not Telling The Story For Galenica AG (VTX:GALE)
Jul 31Is Galenica (VTX:GALE) Using Too Much Debt?
Jun 16Galenica AG (VTX:GALE) Investors Are Less Pessimistic Than Expected
Apr 25We Think The Compensation For Galenica AG's (VTX:GALE) CEO Looks About Right
Apr 04Slowing Rates Of Return At Galenica (VTX:GALE) Leave Little Room For Excitement
Mar 29Pinning Down Galenica AG's (VTX:GALE) P/E Is Difficult Right Now
Jan 22Is There An Opportunity With Galenica AG's (VTX:GALE) 42% Undervaluation?
Jan 04Returns On Capital At Galenica (VTX:GALE) Have Hit The Brakes
Oct 26Is Galenica (VTX:GALE) Using Too Much Debt?
Oct 11Are Investors Undervaluing Galenica AG (VTX:GALE) By 42%?
Sep 26These 4 Measures Indicate That Galenica (VTX:GALE) Is Using Debt Reasonably Well
Jun 20Here's What To Make Of Galenica's (VTX:GALE) Decelerating Rates Of Return
Apr 17We Think Galenica (VTX:GALE) Can Stay On Top Of Its Debt
Mar 12Returns On Capital At Galenica (VTX:GALE) Have Hit The Brakes
Jan 08These 4 Measures Indicate That Galenica (VTX:GALE) Is Using Debt Reasonably Well
Nov 28The Returns At Galenica (VTX:GALE) Aren't Growing
Sep 20Is Galenica (VTX:GALE) A Risky Investment?
Aug 30Return Trends At Galenica (VTX:GALE) Aren't Appealing
Jun 15Galenica (VTX:GALE) Could Easily Take On More Debt
Apr 06Galenica (VTX:GALE) Has More To Do To Multiply In Value Going Forward
Feb 15Should You Be Adding Galenica (VTX:GALE) To Your Watchlist Today?
Jan 02Does Galenica (VTX:GALE) Have A Healthy Balance Sheet?
Nov 30Returns At Galenica (VTX:GALE) Appear To Be Weighed Down
Oct 24With EPS Growth And More, Galenica (VTX:GALE) Is Interesting
Sep 25Galenica (VTX:GALE) Seems To Use Debt Quite Sensibly
Aug 24Galenica (VTX:GALE) Has More To Do To Multiply In Value Going Forward
Jul 24If You Like EPS Growth Then Check Out Galenica (VTX:GALE) Before It's Too Late
Jun 12Investors Met With Slowing Returns on Capital At Galenica (VTX:GALE)
Apr 07Galenica (VTX:GALE) Seems To Use Debt Quite Sensibly
Mar 25Galenica AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 11Is Galenica AG (VTX:GALE) The Right Choice For A Smart Dividend Investor?
Feb 27Are Institutions Heavily Invested In Galenica AG's (VTX:GALE) Shares?
Jan 31
Galenica (VTX:GALE) Shareholders Have Enjoyed A 25% Share Price Gain
Jan 13Is Galenica (VTX:GALE) Likely To Turn Things Around?
Dec 25Is Galenica (VTX:GALE) A Risky Investment?
Dec 09Is Galenica AG (VTX:GALE) An Attractive Dividend Stock?
Nov 24Opbrengsten en kosten
Hoe Galenica geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3,803 | 170 | 5 | 0 |
| 31 Mar 24 | 3,780 | 167 | 5 | 0 |
| 31 Dec 23 | 3,756 | 165 | 5 | 0 |
| 30 Sep 23 | 3,724 | 158 | 5 | 0 |
| 30 Jun 23 | 3,693 | 152 | 5 | 0 |
| 31 Mar 23 | 3,644 | 154 | 5 | 0 |
| 31 Dec 22 | 3,595 | 157 | 5 | 0 |
| 30 Sep 22 | 3,671 | 162 | 5 | 0 |
| 30 Jun 22 | 3,746 | 167 | 5 | 0 |
| 31 Mar 22 | 3,794 | 167 | 5 | 0 |
| 31 Dec 21 | 3,841 | 168 | 5 | 0 |
| 30 Sep 21 | 3,746 | 177 | 5 | 0 |
| 30 Jun 21 | 3,652 | 185 | 5 | 0 |
| 31 Mar 21 | 3,568 | 179 | 5 | 0 |
| 31 Dec 20 | 3,485 | 172 | 5 | 0 |
| 30 Sep 20 | 3,441 | 149 | 5 | 0 |
| 30 Jun 20 | 3,396 | 126 | 6 | 0 |
| 31 Mar 20 | 3,351 | 126 | 6 | 0 |
| 31 Dec 19 | 3,306 | 125 | 6 | 0 |
| 30 Sep 19 | 3,256 | 140 | 32 | 0 |
| 30 Jun 19 | 3,206 | 156 | 58 | 0 |
| 31 Mar 19 | 3,188 | 152 | 58 | 0 |
| 31 Dec 18 | 3,171 | 148 | 58 | 0 |
| 30 Sep 18 | 3,165 | 132 | 57 | 0 |
| 30 Jun 18 | 3,159 | 117 | 56 | 0 |
| 31 Mar 18 | 3,152 | 118 | 56 | 0 |
| 31 Dec 17 | 3,145 | 119 | 56 | 0 |
| 30 Sep 17 | 3,112 | 111 | 56 | 0 |
| 30 Jun 17 | 3,078 | 104 | 56 | 0 |
| 31 Mar 17 | 3,057 | 94 | 56 | 0 |
| 31 Dec 16 | 3,037 | 83 | 56 | 0 |
| 31 Dec 15 | 2,918 | 81 | 55 | 0 |
| 31 Dec 14 | 2,829 | 82 | 55 | 0 |
Kwaliteitswinsten: GALE heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (4.5%) GALE } zijn hoger dan vorig jaar (4.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van GALE is de afgelopen 5 jaar met 3.1% per jaar gegroeid.
Versnelling van de groei: De winstgroei van GALE over het afgelopen jaar ( 11.6% ) overtreft het 5-jarig gemiddelde ( 3.1% per jaar).
Winst versus industrie: De winstgroei GALE over het afgelopen jaar ( 11.6% ) overtrof de Healthcare -sector 15.6%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 12.1% ) van GALE wordt als laag beschouwd.